Westminster, CA – July
2, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies
and a full-service environmental engineering company, announced that its wholly
owned subsidiary BioLargo Engineering, Science & Technologies (BLEST) has completed
manufacturing on its first prototype unit of its patented BioLargo AECTM
(“Aqueous Electrostatic Concentrator”). This prototype is being tested and will
be installed on-site for its first field pilot in the coming months, where the
technology will be vetted in tough field conditions for its ability to
effectively and affordably eliminate per- and poly-fluoroalkyl substances (“PFAS”)
contaminants from water. The technology has already been proven in lab-scale
studies to eliminate +99% of PFAS from water in continuous flow while consuming
as low as $0.30 in electrical costs per 1,000 gallons treated, representing a
significant potential cost savings compared to incumbent PFAS solutions like
reverse osmosis and carbon sequestration technologies.
Described as “forever chemicals” by
Washington DC based environmental watchdog the Environmental Working Group,
PFAS contamination is estimated to affect up to 110 million people in the United
States. Numerous experts have linked PFAS to detrimental effects on human
health and the environment due to their tendency to accumulate and persist in
the environment and human body. On January 7, 2020, EPA Administrator Andrew
Wheeler announced that “aggressively
addressing per-and polyfluoroalkyl substances (PFAS) is an active and ongoing
priority for the U.S. Environmental Protection Agency.” PFAS are found in
common household and industrial products, and municipalities are struggling to
find a feasible and affordable solution to remove these contaminants from their
drinking water.
The BioLargo AEC is intended for two primary markets in the
U.S. and abroad: 1) treatment of municipal drinking water to remove PFAS
contamination, and 2) treatment and remediation of groundwater contaminated by
PFAS. Recent
estimates suggest that the total addressable market for PFAS water
treatment within the U.S. will grow to $3.1B annually by 2030.
Once the first field pilot projects for the AEC have been
successfully completed, the company intends to commence the first commercial
trials for the AEC.
Speaking on the future of the BioLargo AEC, BioLargo
Engineering President Randall Moore commented, “As with any new technology, the
first field pilots are a critical step for the AEC. We are confident our
prototype will quickly gain recognition for its unmatched cost-efficiency for
removal of PFAS, a technical challenge that has not yet been solved in a
broadly feasible and affordable way. The AEC was designed from the ground-up to
be a low-OPEX system that consumes very little electricity, and its components
are easily sourced, durable, and affordable for most prospective installations.”
BioLargo, Inc. President & CEO Dennis P. Calvert
commented, “Experts predict removing PFAS from groundwater and contaminated
soil will takes decades to complete. Current PFAS technologies are expensive, inefficient,
and cumbersome. Our engineering team are
experts in this area, and this innovative AEC technology would not be possible
without their extensive industry experience. We have key relationships in the
water industry that can help prove out our AEC performance metrics and leverage
the global opportunity through partnerships.”
About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products
and environmental engineering solutions provider driven by a mission to “make
life better”. We feature unique
disruptive solutions to deliver clean air, clean water and a clean, safe
environment (www.biolargo.com). Our
engineering division features experienced professional engineers dedicated to
integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our
industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features
CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com),
which eliminates the odor-causing compounds and VOCs rather than masking them,
and is now winning over leading companies in the solid waste handling and
wastewater industries and other industries that contend with malodors and VOCs.
Our subsidiary BioLargo Water (www.biolargowater.ca)
develops the Advanced Oxidation System "AOS," a disruptive industrial
water treatment technology designed to eliminate waterborne pathogens and
recalcitrant contaminants with better energy-efficiency and lower operational
costs than incumbent technologies. We are a minority stockholder of and technology
licensor to our subsidiary Clyra Medical which features its breakthrough
product Clyraguard ( www.clyramedical.com/clyraguard)
an FDA Registered, hospital grade disinfectant for PPE including facemasks,
proven 99.999% effective and safe for skin, as well as its other products
offering gentle solutions for chronic infected wounds to promote infection
control and regenerative tissue therapy.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release includes “forward-looking
statements” within the meaning of the safe harbor provisions of the United
States Private Securities Litigation Reform Act of 1995. Actual results may
differ from expectations, estimates and projections and, consequently, you
should not rely on these forward-looking statements as predictions of future
events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,”
“predicts,” “potential,” “continue,” and similar expressions are intended to
identify such forward-looking statements. These forward-looking statements
involve significant risks and uncertainties that could cause the actual results
to differ materially from the expected results.
No comments:
Post a Comment